Luminex Plc · CSELK:LUMX.N0000
Luminex — Q3 2019 Earnings Presentation
8 slides from Luminex's earnings presentation, Nov 4, 2019
Slide 1: Q3 2019 Conference Call Investor Presentation
Q3 2019 Conference Call Investor Presentation November 4, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our
Slide 3: Current Highlights
Current Highlights Q3 2019 Financial Results Valued New Products • ® Revenue: Up 9% to $78.7M, reflects $8.7M addition from ARIES MRSA Assay received FDA clearance Flow Cytometry and $6.9M reduction in certain sales to LabCorp • Submitted VERIGENE ® II GI Panel to FDA . Molecular Sample to Answer: +
Slide 4: Keys To Long-Term Success
Keys To Long-Term Success • Timely commercial launch of new products • Continue to have commercial success in the marketplace • Maintain our position as the gold standard multiplexing platform and continue to support our Partners’ significant investments in this platform • Targeted investments in ou
Slide 5: Financial Overview
Luminex. plexity simplified, Financial Overview
Slide 6: Long-Term Financial Targets
Long-Term Financial Targets Long-Term Target* Total Revenue ~$500M Gross Margin ~60% Operating Margin ~20% * Long-term targets don’t include M&A activity. complexity simplified . | © Copyright 2019 Luminex Corporation 6
Slide 7: 2019 Guidance and Beyond
2019 Guidance and Beyond FULL-YEAR 2019 • Expect to submit VERIGENE ® II Respiratory Panel to REVENUE GUIDANCE: FDA by year end • NextGen xMAP ® System development For the full year 2019, on-track the Company is adjusting its revenue expectations • to a range of $334M to $337M Flow Cytometry acquisi
Slide 8: Luminex Investment Highlights
Luminex Investment Highlights New and Transformative Era for Luminex Anticipated as a More Diversified Company, With Strong Organic Growth, Profitability, and Cash Flow MULTI-BILLION DOLLAR MARKETS 80+ PARTNERS Serve life science research Investing in our technology and clinical diagnostics RAZOR /